Bio-Techne - TECH Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TECH shares.
View TECH analyst ratings or view top-rated stocks.

9 brokers have issued twelve-month price targets for Bio-Techne's stock. Their TECH share price forecasts range from $88.00 to $120.00. On average, they expect the company's share price to reach $104.36 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.

Bio-Techne's stock was trading at $82.88 at the start of the year. Since then, TECH shares have decreased by 11.4% and is now trading at $73.41.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our TECH earnings forecast.

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings results on Monday, November, 1st. The biotechnology company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. The biotechnology company earned $257.72 million during the quarter, compared to the consensus estimate of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 15.87% and a net margin of 23.38%. During the same period in the prior year, the firm posted $0.29 earnings per share.

Bio-Techne announced a quarterly dividend on Thursday, February 2nd. Shareholders of record on Monday, February 13th will be paid a dividend of $0.08 per share on Monday, February 27th. This represents a $0.32 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Friday, February 10th. This is a positive change from the stock's previous quarterly dividend of $0.02.
Read our dividend analysis for TECH.

ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Alger Mid Cap 40 ETF (FRTY), American Century Mid Cap Growth Impact (MID), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Alger 35 ETF (ATFV) and Putnam BioRevolution ETF (SYNB).

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.44%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 19.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 15.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

Bio-Techne's stock split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly minted shares were distributed to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Bio-Techne's stock is owned by many different institutional and retail investors. Top institutional investors include Select Equity Group L.P. (4.55%), Bamco Inc. NY (3.51%), Neuberger Berman Group LLC (2.63%), Geode Capital Management LLC (2.34%), Winslow Capital Management LLC (2.00%) and Morgan Stanley (1.90%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TECH stock can currently be purchased for approximately $73.41.

Bio-Techne (NASDAQ:TECH) has a market capitalization of $11.55 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.61 on an earnings per share basis.

The company employs 3,000 workers across the globe.

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.